Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells

BACKGROUND: Natalizumab, a monoclonal humanized antibody targeting the alpha-4 chain of very late activation antigen 4 (VLA-4) exerts impressive therapeutic effects in patients with relapsing-remitting multiple sclerosis. Our objective was to study impacts of Natalizumab therapy on Foxp3+ T regulato...

Descripción completa

Detalles Bibliográficos
Autores principales: Stenner, Max-Philipp, Waschbisch, Anne, Buck, Dorothea, Doerck, Sebastian, Einsele, Hermann, Toyka, Klaus V., Wiendl, Heinz
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553177/
https://www.ncbi.nlm.nih.gov/pubmed/18836525
http://dx.doi.org/10.1371/journal.pone.0003319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553177/
https://www.ncbi.nlm.nih.gov/pubmed/18836525
http://dx.doi.org/10.1371/journal.pone.0003319

Ejemplares similares